The animal antibiotics market growth can largely be attributed to the rising demand for animal-derived food products, increasing incidence of zoonotic diseases, and the implementation of regulations to prevent the spread of animal diseases. Rising animal healthcare spending and the growing demand for pet insurance are further expected to drive the growth of this market. The untapped emerging markets such as China, India, and Brazil and growth in the overall companion animal population are also expected to offer significant growth opportunities to market players in the coming years.
The global animal antimicrobials and antibiotics market is projected to reach USD 5.6 billion by 2026 from USD 4.7
billion in 2021, at a CAGR of 3.6% from 2021 to 2026.
Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=25161353
Market Segmentation:
Based on products, the global animal antimicrobials
and antibiotics market is segmented into tetracyclines, penicillins,
sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones,
cephalosporins, and other antimicrobial and antibiotic products. In 2020, the
tetracyclines segment accounted for 48.9% of the global animal antimicrobials
market. Tetracyclines exhibit advantages such as the highest potency against
pathogenic microorganisms, are well-absorbed, show low toxicity, and are
relatively inexpensive compared to other animal antimicrobial and antibiotic
products. These advantages contribute to the large share of this product
segment. The fluoroquinolones segment is expected to grow at the highest CAGR
of 8.0% during the forecast period. Advantages such as higher efficacy at low
concentrations, quick penetration through tissues, and the availability of
variations in the route of administration result in the higher adoption of
fluoroquinolones among end users.
Based on the mode of delivery, the global animal
antimicrobials and antibiotics market is segmented into premixes, oral powders,
oral solutions, injections, and other modes of delivery. In 2020, the premixes
segment accounted for the largest share of 46.3% of the global animal
antibiotics market. The large share of this segment can be attributed to the
advantages of premixes, such as simplified mode of administration and lower
instability and hygroscopicity of formulations. The injections segment is
expected to witness the highest CAGR of 4.9% during the forecast period.
Advantages such as immediate delivery of drugs and rapid onset of drug effects
are expected to drive growth in this market.
Based on animal type, the global animal
antimicrobials and antibiotics market is categorized into food-producing
animals and companion animals. In 2020, the food-producing animals segment
accounted for the largest share of around 73.4%. This segment is also expected
to register the highest CAGR of 3.9% during the forecast period. The large
share of this segment is mainly due to the rising demand for animal-derived
food products, increase in animal healthcare expenditure, and greater concerns
about zoonotic diseases.
Regional
Analysis:
The animal antimicrobials and antibiotics market is
segmented into five major regions: North
America, Europe, Asia Pacific, Latin America,
and the Middle East & Africa.
In 2020, North America accounted
for the largest share of 30.3% of the global animal antimicrobials market. The
large share of this region is mainly due to the increase in the region's animal
population, rising demand for animal-derived food products, growth in pet
insurance, and rising animal health expenditure compared to other regions.
The Asia
Pacific region is projected to grow at the highest
CAGR of 5.4% during the forecast period. Factors such as the rapidly increasing
animal population and rising demand for animal-derived food products are
driving the growth of this market in the APAC.
Inquiry Before Buying: - https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=25161353
Top Key Players:
Some of the prominent players in the animal
antimicrobials and antibiotics market are Boehringer Ingelheim (Germany),
Zoetis Inc. (US), Elanco Animal Health (US), Merck & Co. Inc (US), Phibro
Animal Health (US), Virbac (France),
Vetoquinol S.A. (France),
Ceva Santé Animale (France),
Dechra Pharmaceuticals Plc (UK), Kyoritsu Seiyaku (Japan),
Tianjin Ringpu (China),
HIPRA (Spain),
Zydus Animal Health (US), China Animal Husbandry (China),
and Inovet (Belgium).
No comments:
Post a Comment